{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-008724","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2025-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.282976+00:00","generated_at":"2026-05-16T15:45:29.727113+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioNexus Gene Lab secures $500M equity facility from ARC and exclusive VitaGuard MRD license in SE Asia","bullets":["ARC Group committed to buy up to $500M of BGLC common stock over 36 months at 3.0-3.5% discount to VWAP; 175k commitment shares issued at $4.32.","BGLC obtains exclusive, perpetual, royalty-free license for VitaGuard MRD liquid biopsy platform in Southeast Asia; $2M fee over 24 months, $500K minimum reagent purchases.","As part of strategic alliance, BGLC issued 392,329 shares to Fidelion (now 16.6% owner) and received 180 Fidelion shares (15% stake).","$500M facility complements $20M ATM program; BGLC retains discretion on draws. ARC prohibited from short-selling or hedging."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-008724","json":"https://secwatch.observer/filing/0001477932-25-008724.json","markdown":"https://secwatch.observer/filing/0001477932-25-008724.md","text":"https://secwatch.observer/filing/0001477932-25-008724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225008724/0001477932-25-008724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225008724/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:45:29.727113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71caa1757a0355afc70e58946be5716ea4bbb60a","claim":"BioNexus Gene Lab Corp issued 392,329 shares of common stock of common stock to Fidelion for issuance to Fidelion was made in reliance upon the exemption from registration under Section 4(a)(2) and Rule 506(b) of Regulation D.","evidence_excerpt":"d and outstanding equity of Fidelion. The issuance to Fidelion was made in reliance upon the exemption from registration under Section 4(a)(2) and Rule 506(b) of Regulation D promulgated thereunder. Item 3.02 Unregistered Sales of Equity Securities. As described under Item 1.01 of this Current Report on Form 8-K,","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225008724/0001477932-25-008724-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"392,329 shares of common stock"},{"label":"Purchaser","value":"Fidelion"},{"label":"Consideration","value":"issuance to Fidelion was made in reliance upon the exemption from registration under Section 4(a)(2) and Rule 506(b) of Regulation D"}],"fact_type":"equity_issuance"},{"claim_id":"f11d9346440ca749c7c4725e4e73507018dbda82","claim":"BioNexus Gene Lab Corp issued 175,000 shares of common stock of common stock to ARC for consideration for ARC’s commitment under the Purchase Agreement.","evidence_excerpt":"the Company issued (i) 175,000 shares of common stock to ARC as consideration for ARC’s commitment under the Purchase Agreement","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225008724/0001477932-25-008724-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"175,000 shares of common stock"},{"label":"Purchaser","value":"ARC"},{"label":"Consideration","value":"consideration for ARC’s commitment under the Purchase Agreement"}],"fact_type":"equity_issuance"},{"claim_id":"1bb66856f10a9c56a99b24f7439a054bea2d19d2","claim":"BioNexus Gene Lab Corp entered into ARC Group International Equity Purchase Agreement with ARC Group International Ltd. valued at up to $500,000,000 of common stock over 36 months (effective 2025-11-28).","evidence_excerpt":". On November 28, 2025, the Company entered into two (2) material definitive agreements described herein below. A. ARC Group International Equity Purchase Agreement On November 28, 2025, BioNexus Gene Lab Corp. (the “Company”) entered into an Equity Purchase Agreement (the “Purchase Agreement”) with ARC Group International Ltd. (“ARC”), the parent of ARC Group Securities, a FINRA registered broker/dealer. Under the terms of the Purchase Agreement, ARC has committed to purchase, from time to time at the Company’s discretion, up to $500,000,000 of the Company’s common stock, no par value per share (“Common Stock”), over a 36-month period (the “Facility”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225008724/0001477932-25-008724-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"ARC Group International Ltd."},{"label":"Value","value":"up to $500,000,000 of common stock over 36 months"},{"label":"Effective","value":"2025-11-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}